Tri-estarylla Kit
Product Images NDC 70700-121

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tri-estarylla (NDC 70700-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tri-estarylla-blister (Tri Estarylla Blister)

Instructional diagram for the Tri-Estarylla kit containing norgestimate and ethinyl estradiol tablets. It shows a weekly pill schedule layout with pill placements for Sunday through Saturday across four weeks, guiding the user through daily tablet intake starting from Sunday of Week 1 to Saturday of Week 4.*

FDA Label Image

Fig 2 (Tri Estarylla Fig 1)

A forest plot chart showing effect estimates (odds ratios or relative risks) with 95% confidence intervals for various women's health studies from 2002 to 2017. Each study is listed on the left, with corresponding horizontal lines and markers illustrating the effect estimates around 1.0 on the x-axis, which ranges from -1.5 to 2.0.*

FDA Label Image

Tri-estarylla-carton.jpg (Tri Estarylla Carton)

Tri-Estarylla kit contains norgestimate and ethinyl estradiol tablets in multiple dosages: 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.25 mg/0.035 mg. The label states it includes three blister packs of 28 tablets each for a 28-day regimen. The product is labeled for prescription use and is distributed by Xiromed, LLC. The packaging includes dosage and storage instructions, a QR code for patient information, and barcodes.*

FDA Label Image

Chemical Structure 1 (Tri Estarylla Chemical Struc)

Chemical structure diagrams of the active ingredients norgestimate and ethinyl estradiol, as labeled in the image. These structures depict the molecular configurations of both compounds found in Tri-Estarylla.*

FDA Label Image

Chart (Tri Estarylla Fig 2)

An illustration showing a vertical scale comparing different birth control methods by pregnancy rates per 100 women per year. Methods range from fewer pregnancies with implants, injections, intrauterine devices, and sterilization, followed by birth control pills, skin patches, and vaginal rings with hormones; then condoms and diaphragms; followed by abstinence during fertile days, spermicide, and withdrawal; to no birth control resulting in the most pregnancies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.